About this FactMed analysis covering adverse side effect reports of ALMARL patients who developed HYPOTENSION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 3 individuals taking ALMARL reported HYPOTENSION to the FDA. A total of 227 ALMARL drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between ALMARL and HYPOTENSION. In doing so, we compare ALMARL with other drugs that cause HYPOTENSION, to help you evaluate whether or not ALMARL causes HYPOTENSION. Likewise, this page shows the most highly-reported side effects of ALMARL, so you can see if HYPOTENSION ranks among ALMARL's most well-known side effects.
Summary Statistics
Reports of ALMARL causing HYPOTENSION: 3
Reports of any side effect of ALMARL : 227
Percentage of ALMARL patients where HYPOTENSION is a reported side effect: 1.3216%

FDA reports of any drug causing HYPOTENSION : 58738
Average percentage for all medicated patients where HYPOTENSION is reported as a complication: 0.3681%

Physician opinion on ALMARL as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing ALMARL:
HYPERTENSION ( 76 patients )
PARKINSON'S DISEASE ( 8 patients )
ESSENTIAL TREMOR ( 6 patients )
ATRIAL FIBRILLATION ( 4 patients )
SCHIZOPHRENIA ( 2 patients )
TREMOR ( 2 patients )
ANGINA PECTORIS ( 2 patients )
DRUG USE FOR UNKNOWN INDICATION ( 2 patients )
PALPITATIONS ( 2 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 2 patients )
TACHYCARDIA ( 2 patients )
HYPERTROPHY ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with HYPOTENSION:

HEPARIN SODIUM INJECTION (11518 patients)
ASPIRIN (7072 patients)
LASIX (3520 patients)
LISINOPRIL (3197 patients)
FUROSEMIDE (2722 patients)
DIGOXIN (2664 patients)
VIOXX (2535 patients)
FOSAMAX (2470 patients)
PREDNISONE (2256 patients)
ACETAMINOPHEN (2228 patients)
LIPITOR (2179 patients)
PLAVIX (2157 patients)
ATENOLOL (2155 patients)
SIMVASTATIN (2135 patients)
HEPARIN SODIUM (2114 patients)
OMEPRAZOLE (2049 patients)
COUMADIN (2038 patients)
POTASSIUM CHLORIDE (1734 patients)
HYDROCHLOROTHIAZIDE (1617 patients)
ALLOPURINOL (1607 patients)
NEXIUM (1567 patients)
FOLIC ACID (1543 patients)
REMICADE (1533 patients)
SYNTHROID (1522 patients)
METOPROLOL TARTRATE (1493 patients)
WARFARIN SODIUM (1483 patients)
DIANEAL (1404 patients)
DIOVAN (1400 patients)
PROTONIX (1399 patients)
COREG (1357 patients)
ZOFRAN (1348 patients)
LEVOTHYROXINE SODIUM (1338 patients)
METFORMIN HCL (1333 patients)
DEXAMETHASONE (1325 patients)
TOPROL-XL (1310 patients)
ALBUTEROL (1296 patients)
NORVASC (1289 patients)
ZOCOR (1288 patients)
PRILOSEC (1266 patients)
AMLODIPINE (1266 patients)
SEROQUEL (1264 patients)
LORAZEPAM (1250 patients)
MORPHINE (1245 patients)
METHOTREXATE (1213 patients)
AMBIEN (1174 patients)
ZOMETA (1146 patients)
NEURONTIN (1138 patients)
NITROGLYCERIN (1138 patients)
INSULIN (1127 patients)
FENTANYL (1116 patients)
IBUPROFEN (1100 patients)
XANAX (1100 patients)
ATIVAN (1097 patients)
CYCLOPHOSPHAMIDE (1067 patients)
HEPARIN (1062 patients)
RAMIPRIL (1037 patients)
VANCOMYCIN (988 patients)
METOPROLOL (976 patients)
SPIRONOLACTONE (974 patients)
AVONEX (972 patients)
CARBOPLATIN (965 patients)
VELCADE (950 patients)
DECADRON (926 patients)
REVLIMID (923 patients)
LEVAQUIN (917 patients)
LOVENOX (914 patients)
PREVACID (912 patients)
LANTUS (910 patients)
GABAPENTIN (908 patients)
PREDNISONE TAB (900 patients)
PREDNISOLONE (883 patients)
LYRICA (880 patients)
CISPLATIN (878 patients)
VICODIN (873 patients)
CARVEDILOL (866 patients)
ZOLOFT (861 patients)
PERCOCET (811 patients)
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% (809 patients)
FORTEO (808 patients)
OXYCONTIN (806 patients)
CLONAZEPAM (798 patients)
CELEBREX (781 patients)
ENALAPRIL MALEATE (777 patients)
LOPRESSOR (774 patients)
ALDACTONE (770 patients)
ALTACE (765 patients)
PROPOFOL (762 patients)
VITAMIN D (760 patients)
OXYCODONE HCL (755 patients)
FLUOROURACIL (753 patients)
CYTARABINE (746 patients)
BENADRYL (746 patients)
CLONIDINE (742 patients)
PAXIL (742 patients)
CYMBALTA (733 patients)
LEXAPRO (727 patients)
ALPRAZOLAM (724 patients)
ACYCLOVIR (722 patients)
HUMIRA (717 patients)
DIAZEPAM (702 patients)
PANTOPRAZOLE (699 patients)
TYSABRI (697 patients)
ADVAIR DISKUS 100/50 (692 patients)
CALCIUM (685 patients)
FLUCONAZOLE (683 patients)
COLACE (683 patients)
MORPHINE SULFATE (666 patients)
AMIODARONE HCL (661 patients)
RANITIDINE (656 patients)
ZANTAC (642 patients)
CRESTOR (642 patients)
CLOZARIL (631 patients)
ZYPREXA (628 patients)
FLOMAX (628 patients)
TRAMADOL HCL (618 patients)
METOPROLOL SUCCINATE (608 patients)
MULTI-VITAMINS (606 patients)
AREDIA (602 patients)
REGLAN (597 patients)
NIFEDIPINE (596 patients)
RISPERDAL (594 patients)
CIPROFLOXACIN (594 patients)
COZAAR (587 patients)
AVELOX (580 patients)
ETOPOSIDE (579 patients)
SPIRIVA (575 patients)
SINGULAIR (575 patients)
TYLENOL (574 patients)
VERAPAMIL (568 patients)
ONDANSETRON (566 patients)
LORTAB (561 patients)
EFFEXOR (558 patients)
PEPCID (548 patients)
DURAGESIC-100 (546 patients)
CITALOPRAM HYDROBROMIDE (545 patients)
MULTI-VITAMIN (543 patients)
FERROUS SULFATE TAB (541 patients)
COMPAZINE (540 patients)
ARANESP (533 patients)
HYDROCORTISONE (532 patients)
TYLENOL (CAPLET) (531 patients)
EPOGEN (524 patients)
LANSOPRAZOLE (522 patients)
IRON (512 patients)
SANDOSTATIN LAR (510 patients)
DILTIAZEM (510 patients)
TRACLEER (506 patients)
VITAMIN B-12 (503 patients)
GLIPIZIDE (498 patients)
BACTRIM (497 patients)
BISOPROLOL FUMARATE (496 patients)
SOLU-MEDROL (495 patients)
GLYBURIDE (494 patients)
AMOXICILLIN (493 patients)
CLOPIDOGREL (493 patients)
TEMAZEPAM (491 patients)
TAXOTERE (484 patients)
ATORVASTATIN CALCIUM (480 patients)
VINCRISTINE (478 patients)
CELEXA (474 patients)
KLONOPIN (465 patients)
METFORMIN (462 patients)
TAXOL (456 patients)
AUGMENTIN '125' (454 patients)
CALCIUM CARBONATE (454 patients)
BACLOFEN (453 patients)
ASCORBIC ACID (453 patients)
PREMARIN (451 patients)
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% (451 patients)
METOCLOPRAMIDE (450 patients)
DOCETAXEL (447 patients)
TRAZODONE HCL (446 patients)
ACETYLSALICYLIC ACID SRT (445 patients)
METHYLPREDNISOLONE (442 patients)
PROZAC (438 patients)
PANTOPRAZOLE SODIUM (436 patients)
LIDOCAINE (436 patients)
OXYGEN (433 patients)
DIFLUCAN (432 patients)
PROMETHAZINE (431 patients)
VALIUM (428 patients)
GLUCOPHAGE (427 patients)
DILAUDID (427 patients)
FAMOTIDINE (426 patients)
AMITRIPTYLINE HCL (425 patients)
AMLODIPINE BESYLATE (425 patients)
ERBITUX (424 patients)
ZETIA (424 patients)
WELLBUTRIN (420 patients)
LACTULOSE (420 patients)
CYCLOSPORINE (419 patients)
MIRTAZAPINE (417 patients)
BENICAR (416 patients)
NYSTATIN (415 patients)
METRONIDAZOLE (415 patients)
DIOVAN HCT (411 patients)
OXALIPLATIN (408 patients)
ZYRTEC (406 patients)
POTASSIUM (404 patients)
MIDAZOLAM HCL (402 patients)
CARDIZEM (401 patients)
PACLITAXEL (400 patients)
ALLEGRA (400 patients)
FLAGYL (399 patients)
HYDROCODONE (397 patients)
RENAGEL (397 patients)
ATACAND (396 patients)
RITUXIMAB (396 patients)
ATROVENT (396 patients)
ENBREL (396 patients)
Most common side effects for patients taking ALMARL:
DEPRESSED LEVEL OF CONSCIOUSNESS (20 patients)
HALLUCINATION (15 patients)
FALL (13 patients)
HYPOGLYCAEMIA (13 patients)
PYREXIA (12 patients)
TREMOR (12 patients)
DIARRHOEA (11 patients)
HEPATIC FUNCTION ABNORMAL (11 patients)
PNEUMONIA (10 patients)
DYSARTHRIA (10 patients)
BLOOD CREATINE PHOSPHOKINASE INCREASED (9 patients)
RENAL FAILURE ACUTE (9 patients)
LIVER DISORDER (9 patients)
CEREBRAL INFARCTION (8 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (8 patients)
DRUG INEFFECTIVE (8 patients)
RENAL IMPAIRMENT (8 patients)
HYPONATRAEMIA (8 patients)
INTERSTITIAL LUNG DISEASE (8 patients)
JAUNDICE (8 patients)
OEDEMA PERIPHERAL (8 patients)
CONDITION AGGRAVATED (7 patients)
DELIRIUM (7 patients)
DYSPHAGIA (7 patients)
DYSPNOEA (7 patients)
HYPOAESTHESIA (7 patients)
RHABDOMYOLYSIS (7 patients)
VOMITING (6 patients)
DELUSION (6 patients)
RESPIRATORY FAILURE (6 patients)
DYSKINESIA (6 patients)
SOMNOLENCE (6 patients)
HEPATIC NEOPLASM MALIGNANT (6 patients)
HYPERGLYCAEMIA (6 patients)
HYPOKALAEMIA (6 patients)
MOVEMENT DISORDER (6 patients)
MUSCULAR WEAKNESS (6 patients)
WHITE BLOOD CELL COUNT INCREASED (5 patients)
BLADDER CANCER (5 patients)
BLOOD ANTIDIURETIC HORMONE INCREASED (5 patients)
RESTLESSNESS (5 patients)
BLOOD OSMOLARITY DECREASED (5 patients)
PLEURAL EFFUSION (5 patients)
C-REACTIVE PROTEIN INCREASED (5 patients)
CONVULSION (5 patients)
RENAL DISORDER (5 patients)
VITH NERVE PARALYSIS (5 patients)
INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (5 patients)
INTESTINAL OBSTRUCTION (5 patients)
SEPSIS (5 patients)
ROAD TRAFFIC ACCIDENT (5 patients)
MUSCULOSKELETAL PAIN (5 patients)
NAUSEA (5 patients)
ANOREXIA (4 patients)
ATELECTASIS (4 patients)
ATRIAL FIBRILLATION (4 patients)
ATRIOVENTRICULAR BLOCK (4 patients)
BLOOD CREATININE INCREASED (4 patients)
BRADYCARDIA (4 patients)
CARDIAC FAILURE (4 patients)
CONSTIPATION (4 patients)
DECREASED APPETITE (4 patients)
DEHYDRATION (4 patients)
DIZZINESS (4 patients)
PLATELET COUNT DECREASED (4 patients)
PAIN (4 patients)
HYPERTENSION (4 patients)
HYPOTHYROIDISM (4 patients)
ILEUS (4 patients)
METABOLIC ACIDOSIS (4 patients)
SMALL INTESTINE CARCINOMA (4 patients)
URINE OSMOLARITY INCREASED (4 patients)
ABASIA (3 patients)
AGGRESSION (3 patients)
PRURITUS (3 patients)
ANAEMIA (3 patients)
PULMONARY ALVEOLAR HAEMORRHAGE (3 patients)
WHITE BLOOD CELL COUNT DECREASED (3 patients)
ASTHMA (3 patients)
BLOOD BILIRUBIN INCREASED (3 patients)
RENAL FAILURE (3 patients)
BLOOD PRESSURE DECREASED (3 patients)
BLOOD PRESSURE INCREASED (3 patients)
VASCULITIS (3 patients)
CAROTID ARTERY STENOSIS (3 patients)
THERAPEUTIC AGENT TOXICITY (3 patients)
CHILLS (3 patients)
CHROMATURIA (3 patients)
PETECHIAE (3 patients)
CHRONIC LYMPHOCYTIC LEUKAEMIA (3 patients)
PORIOMANIA (3 patients)
RENAL ARTERY STENOSIS (3 patients)
PANCYTOPENIA (3 patients)
DRUG ERUPTION (3 patients)
SUDDEN ONSET OF SLEEP (3 patients)
DRUG WITHDRAWAL SYNDROME (3 patients)
VERTIGO (3 patients)
EPILEPSY (3 patients)
FACE OEDEMA (3 patients)
VOLVULUS (3 patients)
GENERALISED OEDEMA (3 patients)
GINGIVAL BLEEDING (3 patients)
HAEMORRHAGE SUBCUTANEOUS (3 patients)
HALLUCINATION, VISUAL (3 patients)
PSYCHIATRIC SYMPTOM (3 patients)
HEART RATE DECREASED (3 patients)
HELICOBACTER TEST POSITIVE (3 patients)
HEPATITIS FULMINANT (3 patients)
HYPERKALAEMIA (3 patients)
HYPOTENSION (3 patients)
IDIOPATHIC THROMBOCYTOPENIC PURPURA (3 patients)
LOSS OF CONSCIOUSNESS (3 patients)
SENSORY DISTURBANCE (3 patients)
LYMPHOMA (3 patients)
MALAISE (3 patients)
MARKEDLY REDUCED DIETARY INTAKE (3 patients)
RENAL TUBULAR DISORDER (3 patients)
NEOPLASM MALIGNANT (3 patients)
SINUS ARREST (3 patients)
ABDOMINAL DISCOMFORT (2 patients)
ABDOMINAL PAIN (2 patients)
ACUTE MYELOID LEUKAEMIA (2 patients)
STOMACH MASS (2 patients)
PERSONALITY CHANGE (2 patients)
AGITATION (2 patients)
ALTERED STATE OF CONSCIOUSNESS (2 patients)
ANAPHYLACTOID REACTION (2 patients)
ANGER (2 patients)
PRODUCTIVE COUGH (2 patients)
RENAL CYST (2 patients)
APHASIA (2 patients)
ASTHENIA (2 patients)
ATRIOVENTRICULAR BLOCK COMPLETE (2 patients)
THIRST (2 patients)
PROSTATE CANCER (2 patients)
BLOOD AMYLASE INCREASED (2 patients)
BLOOD UREA INCREASED (2 patients)
BODY TEMPERATURE INCREASED (2 patients)
SPEECH DISORDER (2 patients)
TUMOUR LYSIS SYNDROME (2 patients)
CEREBRAL HAEMORRHAGE (2 patients)
CHEST X-RAY ABNORMAL (2 patients)
COLON CANCER (2 patients)
COMA HEPATIC (2 patients)
COMPLETED SUICIDE (2 patients)
CONTUSION (2 patients)
PERFORMANCE STATUS DECREASED (2 patients)
DEFAECATION URGENCY (2 patients)
DEMENTIA ALZHEIMER'S TYPE (2 patients)
RASH PRURITIC (2 patients)
DIABETIC KETOACIDOSIS (2 patients)
DRUG INTERACTION (2 patients)
DRUG LEVEL INCREASED (2 patients)
DYSPEPSIA (2 patients)
DYSSTASIA (2 patients)
ELECTROCARDIOGRAM QT PROLONGED (2 patients)
STEVENS-JOHNSON SYNDROME (2 patients)
EPULIS (2 patients)
EXTRAOCULAR MUSCLE PARESIS (2 patients)
FACIAL PARESIS (2 patients)
FEAR (2 patients)
FEBRILE NEUTROPENIA (2 patients)
FEMORAL NECK FRACTURE (2 patients)
FOOT FRACTURE (2 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (2 patients)
GANGRENE (2 patients)
GASTRIC ULCER HAEMORRHAGE (2 patients)
GINGIVAL HYPERTROPHY (2 patients)
GLOSSOPTOSIS (2 patients)
PLEURISY (2 patients)
PHRENIC NERVE PARALYSIS (2 patients)
HAEMATEMESIS (2 patients)
HAEMATURIA (2 patients)
HAEMOGLOBIN DECREASED (2 patients)
POLLAKIURIA (2 patients)
ORAL INTAKE REDUCED (2 patients)
HEPATIC CYST (2 patients)
HEPATIC ENCEPHALOPATHY (2 patients)
HEPATITIS (2 patients)
HYPERREFLEXIA (2 patients)
HYPERTONIA (2 patients)
HYPERURICAEMIA (2 patients)
RASH PAPULAR (2 patients)
INITIAL INSOMNIA (2 patients)
RETINAL OEDEMA (2 patients)
INTESTINAL FUNCTIONAL DISORDER (2 patients)
RESPIRATION ABNORMAL (2 patients)
IRRITABILITY (2 patients)
RIB FRACTURE (2 patients)
LEG AMPUTATION (2 patients)
LYMPHADENOPATHY (2 patients)
METABOLIC ALKALOSIS (2 patients)
ORAL HERPES (2 patients)
TAKAYASU'S ARTERITIS (2 patients)
MOUTH HAEMORRHAGE (2 patients)
UNRESPONSIVE TO STIMULI (2 patients)
TOXIC SKIN ERUPTION (2 patients)
NEPHROLITHIASIS (2 patients)
SUICIDE ATTEMPT (2 patients)
VENTRICULAR FIBRILLATION (2 patients)
NEUTROPHIL COUNT DECREASED (2 patients)
UPPER RESPIRATORY TRACT INFECTION (2 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (2 patients)
SHOCK HAEMORRHAGIC (2 patients)
ABDOMEN CRUSHING (1 patients)
CARDIAC FAILURE CONGESTIVE (1 patients)
EOSINOPHILIC PNEUMONIA ACUTE (1 patients)
ESSENTIAL TREMOR (1 patients)
WRONG TECHNIQUE IN DRUG USAGE PROCESS (1 patients)
FUNGAL INFECTION (1 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for ALMARL


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about HYPOTENSION and ALMARL, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking ALMARL, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in ALMARL. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for ALMARL experts. If you are a healthcare provider experienced in prescribing ALMARL, please register here.

Your online appointment book for Raleigh Rentals & Services

© 2014 FactMed, Inc
Privacy Policy
Terms of Use